High expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy

Medical Oncology

Volumn 29, Issue 5, 2012, Pages 3207-3215

  Zhu, Dongliang ^a   Zha, Xiaoming ^a   Hu, Meiling ^a   Tao, Aidi ^a   Zhou, Hangbo ^b   Zhou, Xiaojun ^b   Sun, Yujie ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

Author keywords

Breast cancer; Paclitaxel resistance; Prognostic marker; TIMP 1

Indexed keywords

PACLITAXEL; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; BIOSYNTHESIS; BREAST TUMOR; CANCER GRADING; DRUG RESISTANCE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; PACLITAXEL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 84880299568     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0239-3     Document Type: Article

References (29)

1. Han W, et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer. 2004;4:82.
2. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004;6(3):109-18.
3. Verma RP, Hansch C. Taxane analogues against breast cancer: a quantitative structure-activity relationship study. Chem Med Chem. 2008;3(4):642-52.
4. Robinson WR, Davis N, Rogers AS. Paclitaxel maintenance chemotherapy following intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2008;18(5):891-5.
5. Choong NW, et al. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. J Thorac Oncol. 2008;3(1):59-67.
6. Agarwala SS, et al. Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. Ann Oncol. 2007;18(7):1224-9.
7. Hortobagyi GN, Holmes FA. Single-agent paclitaxel for the treatment of breast cancer: an overview. Semin Oncol. 1996;23(1 Suppl 1):4-9.
8. Bergh J, et al. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol. 2001;40(2-3):253-81.
9. Bast RC Jr, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19(6):1865-78.
10. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents. 2002;2(1):1-17.
11. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets. 2003;3(3):193-203.
12. Pathan N, et al. Microtubule-targeting drugs induce Bcl-2 phosphorylation and association with Pin1. Neoplasia. 2001;3(1):70-9.
13. Janssen K, et al. Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment. Blood. 2007;110(10):3662-72.
14. Wurtz SO, et al. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer. 2005;12(2):215-27.
15. Pesta M, et al. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples. Anticancer Res. 2007;27(4A):1863-7.
16. Chromek M, et al. Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation. Infect Immun. 2004;72(1):82-8.
17. Lee SJ, et al. TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src. Biochem Biophys Res Commun. 2003;312(4):1196-201.
18. Lambert E, et al. Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. Biochem J. 2003;372(Pt 3):767-74.
19. Liu XW, et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem. 2003;278(41):40364-72.
20. Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res. 1999;59(24):6267-75.
21. Schrohl AS, et al. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res. 2006;12(23):7054-8.
22. Wurtz SO, et al. TIMP-1 as a tumor marker in breast cancer - an update. Acta Oncol. 2008;47(4):580-90.
23. Nakopoulou L, et al. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol. 2002;197(3):307-13.
24. Schrohl AS, et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res. 2004;10(7):2289-98.
25. Wang T, et al. Tissue inhibitor of metalloproteinase-1 protects MCF-7 breast cancer cells from paclitaxel-induced apoptosis by decreasing the stability of cyclin B1. Int J Cancer. 2010;126(2):362-70.
26. Henderson IC, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21(6):976-83.
27. Mamounas EP, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23(16):3686-96.
28. Martin M, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302-13.
29. McGrogan BT, et al. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008;1785(2):96-132.